Abstract
The name of chronic liver disease: primary biliary cirrhosis, has been changed to: primary biliary cholangitis, primarily because of the stigma associated with the word "cirrhosis", as only a minority of the patients develop cirrhosis. In this review we present data on epidemiology and discuss the current treatments with focus on ursodeoxycholic acid and the newly described effects of the farnesoid receptor agonist obeticholic acid.
MeSH terms
-
Anti-Inflammatory Agents / administration & dosage
-
Anti-Inflammatory Agents / therapeutic use
-
Budesonide / administration & dosage
-
Budesonide / therapeutic use
-
Chenodeoxycholic Acid / administration & dosage
-
Chenodeoxycholic Acid / analogs & derivatives
-
Chenodeoxycholic Acid / therapeutic use
-
Cholagogues and Choleretics / administration & dosage
-
Cholagogues and Choleretics / therapeutic use
-
Cholangitis / classification
-
Cholangitis / diagnosis
-
Cholangitis / drug therapy*
-
Cholangitis / surgery
-
Fibric Acids / administration & dosage
-
Fibric Acids / therapeutic use
-
Humans
-
Liver Cirrhosis, Biliary / classification
-
Liver Cirrhosis, Biliary / diagnosis
-
Liver Cirrhosis, Biliary / drug therapy*
-
Liver Cirrhosis, Biliary / surgery
-
Liver Transplantation
-
Receptors, Cytoplasmic and Nuclear / agonists
-
Ursodeoxycholic Acid / administration & dosage
-
Ursodeoxycholic Acid / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Cholagogues and Choleretics
-
Fibric Acids
-
Receptors, Cytoplasmic and Nuclear
-
obeticholic acid
-
farnesoid X-activated receptor
-
Chenodeoxycholic Acid
-
Budesonide
-
Ursodeoxycholic Acid